B3GNT5 Polyklonaler Antikörper

B3GNT5 Polyklonal Antikörper für WB, IHC, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

WB, IHC, ELISA

Konjugation

Unkonjugiert

Publikationen(3)

Kat-Nr. : 20422-1-AP

Synonyme

Beta3Gn-T5, beta3Gn T5, Beta-1,3-N-acetylglucosaminyltransferase 5, Beta-1,3-Gn-T5, Beta 1,3 Gn T5

---

• 

  WB analysis of mouse lung using 20422-1-AP

  mouse lung tissue were subjected to SDS PAGE followed by western blot with 20422-1-AP (B3GNT5 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 20422-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 20422-1-AP (B3GNT5 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human lung using 20422-1-AP

  Immunohistochemical analysis of paraffin-embedded human lung tissue slide using 20422-1-AP (B3GNT5 antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human lung using 20422-1-AP

  Immunohistochemical analysis of paraffin-embedded human lung tissue slide using 20422-1-AP (B3GNT5 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: Mauslungengewebe, MCF-7-Zellen
• Erfolgreiche Detektion in IHC: humanes Lungengewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:500-1:3000
• Immunhistochemie (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• KD/KO: See 1 publications below
• WB: See 2 publications below
• IHC: See 2 publications below

Produktinformation

20422-1-AP bindet in WB, IHC, ELISA B3GNT5 und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: B3GNT5 fusion protein Ag14246
• Vollständiger Name: UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5
• Berechnetes Molekulargewicht: 378 aa, 44 kDa
• Beobachtetes Molekulargewicht: 44 kDa
• GenBank-Zugangsnummer: BC028058
• Gene symbol: B3GNT5
• Gene ID (NCBI): 84002
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

B3GNT5 (UDP-GlcNAc:β-Gal β-1,3-N-acetylglucosaminyltransferase 5) is a glycosyltransferase that transfers an N-acetylglucosamine (GlcNAc) from uridine diphosphate (UDP)-GlcNAc to galactose at the nonreducing end of carbohydrate chain. B3GNT5 is required for tumorigenicity of breast cancer and glycosylation of B3GNT5 is critical for its protein stabilization (PMID: 35526049). B3GNT5 was highly expressed in human GBM and glioma cell lines in culture, and was associated with poor patient survival (PMID: 32677340). B3GNT5 was N-glycosylated, and glycosylation of B3GNT5 stabilized its protein for non-glycosylated B3GNT5 protein degraded more rapidly than glycosylated form (PMID: 35526049).

Publikationen

Species	Application	Title
human	IHC	J Cell Mol Med; MiR-30a-5p inhibits proliferation and metastasis of hydatidiform mole by regulating B3GNT5 through ERK/AKT pathways.; Authors - Zhenzhen Guo
human	WB	Cell Rep; Sequential genome-wide CRISPR-Cas9 screens identify genes regulating cell-surface expression of tetraspanins; Authors - Jicheng Yang
human	WB,IHC	iScience; B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer; Authors - Wei Yao ; KD Validated